CC

Clinical Cancer Research

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy; gene therapy; diagnostic biomarkers; innovative imaging, and clinical genetics.

Looking to publish in Clinical Cancer Research? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Oncology
Impact Factor 10.2
Quartile Q1
Open Access Type Closed
ISSN 1078-0432
eISSN 1557-3265
Invitation Only No
Cost Range Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.

Submission Instructions

Clinical Cancer Research accepts the following article types. Click on an article type to view submission instructions.

Original Research Articles

Cover Letter Cover letter is not required but authors are strongly encouraged to upload one. Any use of AI to produce new text, images, or other material for the manuscript must be described in detail in the cover letter.
Abstract An abstract is required.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript should include Title Page, a 150-word translational relevance statement on a separate page before the abstract, Abstract, Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Methods. Manuscript must include a 150-word translational relevance statement, a conflict of interest disclosure on the title page, an AI-use declaration in the acknowledgments and manuscript as applicable, a Data Availability Statement, and a Code Availability Statement when custom code was used.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors.
Figures & Tables For initial submission, figures should be on the same page as the legend either at the end of the manuscript file or embedded in the text near the figure callout, and supplementary data should be uploaded separately. Each figure must have a legend, figures and tables must be cited and numbered in the order they appear, and figure legends must include the number of technical and biological replicates.
Reformat to Clinical Cancer Research using Livewrite Premium

Review Manuscript

Cover Letter Cover letter is strongly encouraged but not required. Cover letters for review articles are not required at submission, but presubmission inquiries should include an outline or draft and a list of key references if available.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript should include Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods. The title page must include the word count, total number of figures and tables, and a conflict of interest statement, and any use of generative artificial intelligence or human-assisted editing services must be declared in the acknowledgments or other appropriate manuscript section.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors.
Figures & Tables For initial submission, figures should appear on the same page as the legend either embedded near the figure callout or placed at the end of the manuscript file, and authors are strongly encouraged to upload a single manuscript file containing the text and all display items. Each figure must be numbered in text order and accompanied by a legend, and every table must have a descriptive title and enough explanatory information to be understood without reference to the text.
Reformat to Clinical Cancer Research using Livewrite Premium

Meta-Analysis

Cover Letter Cover letter is strongly encouraged but not required. Any use of AI to produce new text, images, or other material for the manuscript must be described in detail in the cover letter.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. The manuscript must include a 150-word statement of translational relevance on a page between the title page and abstract. A detailed conflict of interest disclosure statement must appear on the title page, and any use of generative artificial intelligence or human-assisted editing services must be declared in the acknowledgments section.
References References must be numbered in the order of first mention in the text, with up to 6 authors listed in full and more than 6 authors abbreviated after the first 6 with "et al.".
Figures & Tables For initial submission, figures should be embedded on the same page as the legend either near the figure callout or at the end of the manuscript file. Each table must be numbered with a descriptive title, and each figure must be numbered in text order and accompanied by a legend that defines the figure and any panel labels.
Reformat to Clinical Cancer Research using Livewrite Premium

Systematic Reviews

Cover Letter Cover letter is strongly encouraged but not required. Cover letter must describe any use of AI to produce new text, images, or other material and explain how any associated manuscript is related to the submission.
Abstract Abstract requirements are not specified.
Manuscript Initial submissions do not have strict length restrictions, and the methods section is excluded when calculating manuscript length. Manuscript should include Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods, and Systematic Reviews must follow PRISMA. A 150-word translational relevance statement must appear on a page between the title page and abstract, AI assistance in manuscript preparation must be declared in the acknowledgments, and the title page must include the word count, total number of figures and tables, and a conflict of interest disclosure statement.
References References must be numbered in order of first mention in the text, cited in the text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors or all authors when there are 6 or fewer.
Figures & Tables For initial submission, figures should be placed on the same page as the legend either at the end of the manuscript file or embedded near the figure callout, and authors are strongly encouraged to upload a single manuscript file containing the main text and all display items. Each figure must be numbered in text order and accompanied by a legend with a short title sentence and description, including panel labels and descriptions when applicable, while every table must be numbered in Arabic numerals and include a descriptive title.
Reformat to Clinical Cancer Research using Livewrite Premium

Clinical Trials

Cover Letter Cover letter is strongly encouraged rather than required. Cover letter must describe how any associated manuscript is related to the submission, disclose any restrictions on availability of manuscript components, and detail any use of AI to produce new text, images, or other material.
Abstract Abstract is required.
Manuscript Manuscript should include the standard sections of title page, abstract, Introduction, Materials and Methods or Methods, Results, Discussion, Acknowledgments, and a Data Availability subsection at the end of Materials and Methods, with a 150-word translational relevance statement placed between the title page and abstract. Manuscript must include a detailed conflict of interest disclosure on the title page, the trial registration number when applicable, an acknowledgments disclosure of any generative AI or human-assisted editing help, and a supplementary table describing cancer background and study population representativeness including patient characteristics such as sex or gender, age, race or ethnicity, and geography.
References References must be numbered in order of first mention in the text, cited in text by number only, and list the first 6 authors followed by "et al." when there are more than 6 authors or all authors when there are 6 or fewer.
Figures & Tables For initial submission, figures should be embedded in the manuscript near the figure callout or placed at the end on the same page as the legend, while supplementary data must be uploaded separately. Each figure must be numbered in text order and accompanied by a legend, and Clinical Trials must also include a supplementary table covering cancer background and the representativeness of the study population.
Reformat to Clinical Cancer Research using Livewrite Premium

Recent Publications

Editor’s Note: ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer

Zhuqing Li, Wei Zhou, Yi Zhang, Wei Sun, Mingo M.H. Yung, Jing Sun, Jing Li, Chi-Wei Chen, Zongzhu Li, Yunxiao Meng, Jie Chai, Yuan Zhou, Stephanie S. Liu, Annie N.Y. Cheung, Hextan Y.S. Ngan, David W. Chan, Wei Zheng, Wenge Zhu

10.1158/1078-0432.ccr-26-3222
View Publication

Editor’s Note: Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor

Martina Bazzaro, Zhenhua Lin, Antonio Santillan, Michael K. Lee, Mei-Cheng Wang, Kwun C. Chan, Robert E. Bristow, Ralph Mazitschek, James Bradner, Richard B.S. Roden

10.1158/1078-0432.ccr-26-3035
View Publication

Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors

Ingrid Teige, Kristoffer S. Rohrberg, Ana Carneiro, Jeffrey Yachnin, Susanne Gertsson, Petra Holmkvist, Linda Mårtensson, Rikke L. Eefsen, Zsuzsanna Pápai, István Láng, Harriet Walter, Marie Borggren, Marica Vaapil, Jan Anders Nilsson, Carolin Svensson, Mathilda Kovacek, Therese Blidberg, Kirstie Cleary, Robert J. Oldham, Alexandra Gabriela. Ferreira, Benjamin L. Duell, Anette Sundstedt, Niyaz Yoosuf, Monika Semmrich, Danijela Lindahl, Stephen A. Beers, Sean H. Lim, Johan Wallin, Ingrid Karlsson, Mark S. Cragg, Björn Frendéus, Andres McAllister

10.1158/1078-0432.ccr-26-2049
View Publication

Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry

Daniela Miliziano, Julia K. Rotow, Meghanne Lomibao, Arianna Marinello, Helena Bote-de Cabo, Fabrizio Citarella, Lorenza Landi, Massimiliano Cani, Mariana Brandão, Jamie Feng, Sophie Cousin, Andrea De Giglio, Marco Tagliamento, Philippe Rochigneux, Florian Guisier, Lea Ruge, Annarita Avanzo, Francesca Colamartini, Francesco Cortiula, Vladmir Cordeiro de Lima, Antonio Calles, Patricia Iranzo, Barliz Waissengrin, Clarisse Audigier-Valette, Frank Aboubakar, Noemie Simon-Tillaux, Vinicius Ernani, Jordi Remon, Alessio Cortellini, David Planchard, Biagio Ricciuti, Benjamin Besse, Petros Christopoulos, Alexander Drilon, Mihaela Aldea

10.1158/1078-0432.ccr-26-2942
View Publication

Multi-institutional study evaluating the role of liquid biopsy to determine risk of extraocular disease, therapy response and recurrence in retinoblastoma

Sameer Farouk Sait, Aman Verma, Karthigayini Sivaprakasam, Ria Sachdeva, Jasmine H. Francis, Ronak Shah, Melissa Robbins, Jamal Benhamida, Chhavi Gupta, Neerav Shukla, Matthias Karajannis, Michael Berger, Ira J. Dunkel, Sima Das, David H. Abramson

10.1158/1078-0432.ccr-26-2052
View Publication

Frequently asked questions

How long does it take to publish?

AACR member authors may receive a full refund of the journal publication fee if the time from completion of submission to the first decision after external peer review exceeds 60 days.

Reformat to Clinical Cancer Research using Livewrite Premium

Is a cover letter required?

Authors are strongly encouraged to upload a cover letter for initial submission.

Reformat to Clinical Cancer Research using Livewrite Premium

What are the publication costs?

Publication involves a base publication fee and an additional fee for each display item; authors may apply for a waiver of the fixed publication fee if no financial support exists.

Reformat to Clinical Cancer Research using Livewrite Premium

Research Topics

Cancer Genomics and Diagnostics Cancer Immunotherapy and Biomarkers Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Immunotherapy and Immune Responses Lung Cancer Treatments and Mutations Breast Cancer Treatment Studies CAR-T cell therapy research Cancer, Hypoxia, and Metabolism Cancer-related Molecular Pathways Cancer Cells and Metastasis Epigenetics and DNA Methylation PARP inhibition in cancer therapy Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology RNA modifications and cancer Prostate Cancer Treatment and Research Cancer Research and Treatments Monoclonal and Polyclonal Antibodies Research Pancreatic and Hepatic Oncology Research Ovarian cancer diagnosis and treatment PI3K/AKT/mTOR signaling in cancer Genetic factors in colorectal cancer Immune Cell Function and Interaction Lung Cancer Research Studies

Related Journals

CO
Current Oncology Reports Springer Science+Business Media
Bi
BioDrugs Adis, Springer Healthcare
LC
Lung Cancer Targets and Therapy Dove Medical Press
SI
Seminars in Cancer Biology Elsevier BV
JC
JNCI Cancer Spectrum Oxford University Press
CO
Cellular Oncology Springer Nature